The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...
Randomized Prospective Trial Exploring the Impact of Structured Journaling in Patients With Sarcoma on the Management of Treatment-Related Adverse Events Many patient population groups are not ...
Objective To evaluate sex differences in perioperative characteristics, in-hospital outcomes and long-term survival following coronary artery bypass grafting (CABG).Methods Prospective data were ...
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) OS at 36 months was 81.9% (95% CI, 66.8 ...
Industry watchers who cheered on Summit Therapeutics’ claim that the first global phase 3 trial of its Akeso-partnered PD-1xVEGF drug showed consistent benefit between China and Western populations ...
In the dynamic field of oncology, the quest for precise biomarkers to predict cancer risk, prognosis, and treatment response is paramount. These insights directly inform personalized therapeutic ...
Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin’s lymphoma showed long-term progression-free survival benefits with first-line therapy with ...
BARCELONA, Spain — Long-awaited overall survival data from the KEYNOTE-522 trial has lifted spirits in the triple-negative breast cancer (TNBC) community. The trial confirmed the survival benefit of ...
The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results